|
1
|
Cancer Research UK, . Head and neck
cancers statistics. www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers#heading-OneFebruary
16–2024
|
|
2
|
National Cancer Institute, . Head and Neck
Cancers. https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheetFebruary
16–2024
|
|
3
|
Ranganathan K and Kavitha L: Oral
epithelial dysplasia: Classifications and clinical relevance in
risk assessment of oral potentially malignant disorders. J Oral
Maxillofac Pathol. 23:19–27. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mello FW, Miguel AFP, Dutra KL, Porporatti
AL, Warnakulasuriya S, Guerra ENS and Rivero ERC: Prevalence of
oral potentially malignant disorders: A systematic review and
meta-analysis. J Oral Pathol Med. 47:633–640. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rhodus NL, Kerr AR and Patel K: Oral
Cancer: Leukoplakia, premalignancy, and squamous cell carcinoma.
Dent Clin North Am. 58:315–340. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen TC, Wu CT, Ko JY, Yang TL, Lou PJ,
Wang CP and Chang YL: Clinical characteristics and treatment
outcome of oropharyngeal squamous cell carcinoma in an endemic
betel quid region. Sci Rep. 10:5262020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee KW, Kuo WR, Tsai SM, Wu DC, Wang WM,
Fang FM, Chiang FY, Ho KY, Wang LF, Tai CF, et al: Different impact
from betel quid, alcohol and cigarette: Risk factors for pharyngeal
and laryngeal cancer. Int J Cancer. 117:831–836. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Saito Y, Ebihara Y, Ushiku T, Omura G,
Kobayashi K, Ando M, Sakamoto T, Fukayama M, Yamasoba T and Asakage
T: Negative human papillomavirus status and excessive alcohol
consumption are significant risk factors for second primary
malignancies in Japanese patients with oropharyngeal carcinoma. Jpn
J Clin Oncol. 44:564–569. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Al-Khafaji ASK, Pantazi P, Acha-Sagredo A,
Schache A, Risk JM, Shaw RJ and Liloglou T: Overexpression of HURP
mRNA in head and neck carcinoma and association with in
vitro response to vinorelbine. Oncol Lett. 19:2502–2507.
2020.PubMed/NCBI
|
|
10
|
Lewin F, Norell SE, Johansson H,
Gustavsson P, Wennerberg J, Biörklund A and Rutqvist LE: Smoking
tobacco, oral snuff, and alcohol in the etiology of squamous cell
carcinoma of the head and neck. Cancer. 82:1367–1375. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Balasundaram I, Payne KFB, Al-Hadad I,
Alibhai M, Thomas S and Bhandari R: Is there any benefit in surgery
for potentially malignant disorders of the oral cavity? J Oral
Pathol Med. 43:239–244. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van der Waal I: Potentially malignant
disorders of the oral and oropharyngeal mucosa; terminology,
classification and present concepts of management. Oral Oncol.
45:317–323. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Field EA, McCarthy CE, Ho MW, Rajlawat BP,
Holt D, Rogers SN, Triantafyllou A, Field JK and Shaw RJ: The
management of oral epithelial dysplasia: The Liverpool algorithm.
Oral Oncol. 51:883–887. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ropero S and Esteller M: The role of
histone deacetylases (HDACs) in human cancer. Mol Oncol. 1:19–25.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Perri F, Longo F, Giuliano M, Sabbatino F,
Favia G, Ionna F, Addeo R, Della Vittoria Scarpati G, Di Lorenzo G
and Pisconti S: Epigenetic control of gene expression: Potential
implications for cancer treatment. Crit Rev Oncol Hematol.
111:166–172. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seto E and Yoshida M: Erasers of histone
acetylation: The histone deacetylase enzymes. Cold Spring Harb
Perspect Biol. 6:a0187132014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Delcuve GP, Khan DH and Davie JR: Roles of
histone deacetylases in epigenetic regulation: Emerging paradigms
from studies with inhibitors. Clin Epigenetics. 4:52021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sixto-López Y, Bello M and Correa-Basurto
J: Exploring the inhibitory activity of valproic acid against the
HDAC family using an MMGBSA approach. J Comput Aided Mol Des.
34:857–878. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Parbin S, Kar S, Shilpi A, Sengupta D, Deb
M, Rath SK and Patra SK: Histone Deacetylases: A saga of perturbed
acetylation homeostasis in cancer. J Histochem Cytochem. 62:11–33.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu X, Wang L, Yu C, Yu D and Yu G: Histone
acetylation modifiers in the pathogenesis of Alzheimer's Disease.
Front Cell Neurosci. 9:2262015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Miao X, Liu Y, Li F, Liu Q, Sun J
and Cai L: Dysregulation of histone acetyltransferases and
deacetylases in cardiovascular diseases. Oxid Med Cell Longev.
2014:6419792014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park SY and Kim JS: A short guide to
histone deacetylases including recent progress on class II enzymes.
Exp Mol Med. 52:204–212. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He L, Gao L, Shay C, Lang L, Lv F and Teng
Y: Histone deacetylase inhibitors suppress aggressiveness of head
and neck squamous cell carcinoma via histone
acetylation-independent blockade of the EGFR-Arf1 axis. J Exp Clin
Cancer Res. 38:842019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Verza FA, Das U, Fachin AL, Dimmock JR and
Marins M: Roles of histone deacetylases and inhibitors in
anticancer therapy. Cancers (Basel). 12:16642020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamaguchi T, Cubizolles F, Zhang Y,
Reichert N, Kohler H, Seiser C and Matthias P: Histone deacetylases
1 and 2 act in concert to promote the G1-to-S progression. Genes
Dev. 24:455–469. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Haberland M, Montgomery RL and Olson EN:
The many roles of histone deacetylases in development and
physiology: Implications for disease and therapy. Nat Rev Genet.
10:32–42. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Oehme I, Deubzer HE, Wegener D, Pickert D,
Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von
Deimling A, et al: Histone deacetylase 8 in neuroblastoma
tumorigenesis. Clin Cancer Res. 15:91–99. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kumar B, Yadav A, Lang J, Teknos T and
Kumar P: Suberoylanilide hydroxamic acid (SAHA) reverses
chemoresistance in head and neck cancer cells by targeting cancer
stem cells via the downregulation of nanog. Genes Cancer.
6:169–181. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Eckschlager T, Plch J, Stiborova M and
Hrabeta J: Histone deacetylase inhibitors as anticancer drugs. Int
J Mol Sci. 18:14142017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gan CP, Hamid S, Hor SY, Zain RB, Ismail
SM, Wan Mustafa WM, Teo SH, Saunders N and Cheong SC: Valproic
acid: Growth inhibition of head and neck cancer by induction of
terminal differentiation and senescence. Head Neck. 34:344–353.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma XJ, Wang YS, Gu WP and Zhao X: The role
and possible molecular mechanism of valproic acid in the growth of
MCF-7 breast cancer cells. Croat Med J. 58:349–357. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Caponigro F, Di Gennaro E, Ionna F, Longo
F, Aversa C, Pavone E, Maglione MG, Di Marzo M, Muto P, Cavalcanti
E, et al: Phase II clinical study of valproic acid plus cisplatin
and cetuximab in recurrent and/or metastatic squamous cell
carcinoma of Head and Neck-V-CHANCE trial. BMC Cancer. 16:9182016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Blaheta RA and Cinatl J Jr: Anti-tumor
mechanisms of valproate: A novel role for an old drug. Med Res Rev.
22:492–511. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Phiel CJ, Zhang F, Huang EY, Guenther MG,
Lazar MA and Klein PS: Histone deacetylase is a direct target of
valproic acid, a potent anticonvulsant, mood stabilizer, and
teratogen. J Biol Chem. 276:36734–36741. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gurvich N, Tsygankova OM, Meinkoth JL and
Klein PS: Histone deacetylase is a target of valproic acid-mediated
cellular differentiation. Cancer Res. 64:1079–1086. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Göttlicher M, Minucci S, Zhu P, Krämer OH,
Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG
and Heinzel T: Valproic acid defines a novel class of HDAC
inhibitors inducing differentiation of transformed cells. EMBO J.
20:6969–6978. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sun J, Piao J, Li N, Yang Y, Kim KY and
Lin Z: Valproic acid targets HDAC1/2 and HDAC1/PTEN/Akt signalling
to inhibit cell proliferation via the induction of autophagy in
gastric cancer. FEBS J. 287:2118–2133. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kang H, Gillespie TW, Goodman M, Brodie
SA, Brandes M, Ribeiro M, Ramalingam SS, Shin DM, Khuri FR and
Brandes JC: Long-term use of valproic acid in US veterans is
associated with a reduced risk of smoking-related cases of head and
neck cancer. Cancer. 120:1394–400. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee SH, Nam HJ, Kang HJ, Samuels TL,
Johnston N and Lim YC: Valproic acid suppresses the self-renewal
and proliferation of head and neck cancer stem cells. Oncol Rep.
34:2065–2071. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Erlich RB, Rickwood D, Coman WB, Saunders
NA and Guminski A: Valproic acid as a therapeutic agent for head
and neck squamous cell carcinomas. Cancer Chemother Pharmacol.
63:381–389. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Iannelli F, Zotti AI, Roca MS, Grumetti L,
Lombardi R, Moccia T, Vitagliano C, Milone MR, Ciardiello C,
Bruzzese F, et al: Valproic acid synergizes with cisplatin and
cetuximab in vitro and in vivo in head and neck cancer by targeting
the mechanisms of resistance. Front Cell Dev Biol. 8:7322020.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liverpool Clinical Trials Centre (LCTC), .
SAVER: Sodium Valproate for the Epigenetic Reprogramming of
High-Risk Oral Epithelial Dysplasia. 2019.https://www.lctc.org.uk/research/saver/
|
|
43
|
Chang HH, Chiang CP, Hung HC, Lin CY, Deng
YT and Kuo MY: Histone deacetylase 2 expression predicts poorer
prognosis in oral cancer patients. Oral Oncol. 45:610–614. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hull EE, Montgomery MR and Leyva KJ: HDAC
inhibitors as epigenetic regulators of the immune system: Impacts
on cancer therapy and inflammatory diseases. Biomed Res Int.
2016:87972062016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dokmanovic M, Perez G, Xu W, Ngo L, Clarke
C, Parmigiani RB and Marks PA: Histone deacetylase inhibitors
selectively suppress expression of HDAC7. Mol Cancer Ther.
6:2525–2534. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
McCarthy C, Sacco J, Fedele S, Ho M,
Porter S, Liloglou T, Greenhalf B, Robinson M, Young B, Cicconi S,
et al: SAVER: Sodium valproate for the epigenetic reprogramming of
high-risk oral epithelial dysplasia-a phase II randomised control
trial study protocol. Trials. 22:4282021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Stauber RH, Knauer SK, Habtemichael N,
Bier C, Unruhe B, Weisheit S, Spange S, Nonnenmacher F, Fetz V,
Ginter T, et al: A combination of a ribonucleotide reductase
inhibitor and histone deacetylase inhibitors downregulates EGFR and
triggers BIM-dependent apoptosis in head and neck cancer.
Oncotarget. 3:31–43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Iwahashi S, Shimada M, Utsunomiya T,
Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J and Saito Y:
Histone deacetylase inhibitor enhances the anti-tumor effect of
gemcitabine: A special reference to gene-expression microarray
analysis. Oncol Rep. 26:1057–1062. 2011.PubMed/NCBI
|
|
49
|
Lee BS, Kim YS, Kim HJ, Kim DH, Won HR,
Kim YS and Kim CH: HDAC4 degradation by combined TRAIL and valproic
acid treatment induces apoptotic cell death of TRAIL-resistant head
and neck cancer cells. Sci Rep. 8:125202018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
WHO, . HEAD AND NECK CANCER: 2014 Review
of Cancer Medicines on the WHO List of Essential Medicines. Union
for International Cancer Control; 2014
|
|
51
|
Ho MW, Field EA, Field JK, Risk JM,
Rajlawat BP, Rogers SN, Steele JC, Triantafyllou A, Woolgar JA,
Lowe D and Shaw RJ: Outcomes of oral squamous cell carcinoma
arising from oral epithelial dysplasia: Rationale for monitoring
premalignant oral lesions in a multidisciplinary clinic. Br J Oral
Maxillofac Surg. 51:594–599. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cadoni G, Giraldi L, Petrelli L,
Pandolfini M, Giuliani M, Paludetti G, Pastorino R, Leoncini E,
Arzani D, Almadori G and Boccia S: Prognostic factors in head and
neck cancer: A 10-year retrospective analysis in a
single-institution in Italy. Acta Otorhinolaryngol Ital.
37:458–466. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Dost F, Lê Cao K, Ford PJ, Ades C and
Farah CS: Malignant transformation of oral epithelial dysplasia: A
real-world evaluation of histopathologic grading. Oral Surg Oral
Med Oral Pathol Oral Radiol. 117:343–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Spurling CC, Godman CA, Noonan EJ,
Rasmussen TP, Rosenberg DW and Giardina C: HDAC3 overexpression and
colon cancer cell proliferation and differentiation. Mol Carcinog.
47:137–147. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hayashi A, Horiuchi A, Kikuchi N, Hayashi
T, Fuseya C, Suzuki A, Konishi I and Shiozawa T: Type-specific
roles of histone deacetylase (HDAC) overexpression in ovarian
carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates
cell migration with downregulation of E-cadherin. Int J Cancer.
127:1332–1346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sang Z, Sun Y, Ruan H, Cheng Y, Ding X and
Yu Y: Anticancer effects of valproic acid on oral squamous cell
carcinoma via SUMOylation in vivo and in vitro. Exp
Ther Med. 12:3979–3987. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Marks PA: Histone deacetylase inhibitors:
A chemical genetics approach to understanding cellular functions.
Biochim Biophys Acta. 1799:717–725. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ahn MY and Yoon JH: Histone deacetylase 7
silencing induces apoptosis and autophagy in salivary
mucoepidermoid carcinoma cells. J Oral Pathol Med. 46:276–283.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ahn MY, Chung HY, Choi WS, Lee BM, Yoon S
and Kim HS: Anti-tumor effect of apicidin on Ishikawa human
endometrial cancer cells both in vitro and in vivo by
blocking histone deacetylase 3 and 4. Int J Oncol. 36:125–131.
2010.PubMed/NCBI
|
|
61
|
Ahn MY, Kang DO, Na YJ, Yoon S, Choi WS,
Kang KW, Chung HY, Jung JH, Min do S and Kim HS: Histone
deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell
migration via class II histone deacetylase 4 silencing. Cancer
Lett. 325:189–199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ceccacci E and Minucci S: Inhibition of
histone deacetylases in cancer therapy: Lessons from leukaemia. Br
J Cancer. 114:605–611. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Jurkin J, Zupkovitz G, Lagger S,
Grausenburger R, Hagelkruys A, Kenner L and Seiser C: Distinct and
redundant functions of histone deacetylases HDAC1 and HDAC2 in
proliferation and tumorigenesis. Cell Cycle. 10:406–412. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kaletsch A, Pinkerneil M, Hoffmann MJ,
Jaguva Vasudevan AA, Wang C, Hansen FK, Wiek C, Hanenberg H,
Gertzen C, Gohlke H, et al: Effects of novel HDAC inhibitors on
urothelial carcinoma cells. Clin Epigenetics. 10:1002018.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Pouloudi D, Manou M, Sarantis P, Tsoukalas
N, Tsourouflis G, Dana E, Karamouzis MV, Klijanienko J and
Theocharis S: Clinical significance of histone deacetylase
(HDAC)-1, −2, −4 and −6 Expression in salivary gland tumors.
Diagnostics (Basel). 11:5172021. View Article : Google Scholar : PubMed/NCBI
|
